PI3K and mTOR pathway and molecular targeted agents

Kazuto Nishio; Kazuko Sakai; Yosuke Togashi

PI3K and mTOR pathway and molecular targeted agents

Kazuto Nishio, Kazuko Sakai, Yosuke Togashi

Faculty of Medicine, Dentistry and Pharmaceutical Sciences

Research output: Contribution to journal › Review article › peer-review

1 Citation (Scopus)

Abstract

Molecular alteration of PI3K and mTOR pathways is frequently detected in various types of cancers. PIK3CA mutations are the predictive markers for anti-EGFR antibodies, trastuzumab, and lapatinib. The p110 isoform selective PI3K inhibitors has been developed in the clinical settings to reduced off-target induced adverse events. Feedback loop for PI3K signal leads the resistance to PI3K inhibitors. Dual PI3K/mTOR inhibitors and mutation selective PI3K inhibitors are under evaluation to circumvent the resistance.

Original language	English
Pages (from-to)	1315-1322
Number of pages	8
Journal	Nihon rinsho. Japanese journal of clinical medicine
Volume	73
Issue number	8
Publication status	Published - Aug 1 2015

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{0b7dece64d8045979259dc8fba75768b,

title = "PI3K and mTOR pathway and molecular targeted agents",

abstract = "Molecular alteration of PI3K and mTOR pathways is frequently detected in various types of cancers. PIK3CA mutations are the predictive markers for anti-EGFR antibodies, trastuzumab, and lapatinib. The p110 isoform selective PI3K inhibitors has been developed in the clinical settings to reduced off-target induced adverse events. Feedback loop for PI3K signal leads the resistance to PI3K inhibitors. Dual PI3K/mTOR inhibitors and mutation selective PI3K inhibitors are under evaluation to circumvent the resistance.",

author = "Kazuto Nishio and Kazuko Sakai and Yosuke Togashi",

year = "2015",

month = aug,

day = "1",

language = "English",

volume = "73",

pages = "1315--1322",

journal = "Nihon rinsho. Japanese journal of clinical medicine",

issn = "0047-1852",

publisher = "Nipponrinsho Co., Inc.",

number = "8",

}

TY - JOUR

T1 - PI3K and mTOR pathway and molecular targeted agents

AU - Nishio, Kazuto

AU - Sakai, Kazuko

AU - Togashi, Yosuke

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Molecular alteration of PI3K and mTOR pathways is frequently detected in various types of cancers. PIK3CA mutations are the predictive markers for anti-EGFR antibodies, trastuzumab, and lapatinib. The p110 isoform selective PI3K inhibitors has been developed in the clinical settings to reduced off-target induced adverse events. Feedback loop for PI3K signal leads the resistance to PI3K inhibitors. Dual PI3K/mTOR inhibitors and mutation selective PI3K inhibitors are under evaluation to circumvent the resistance.

AB - Molecular alteration of PI3K and mTOR pathways is frequently detected in various types of cancers. PIK3CA mutations are the predictive markers for anti-EGFR antibodies, trastuzumab, and lapatinib. The p110 isoform selective PI3K inhibitors has been developed in the clinical settings to reduced off-target induced adverse events. Feedback loop for PI3K signal leads the resistance to PI3K inhibitors. Dual PI3K/mTOR inhibitors and mutation selective PI3K inhibitors are under evaluation to circumvent the resistance.

UR - http://www.scopus.com/inward/record.url?scp=84941738355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941738355&partnerID=8YFLogxK

M3 - Review article

C2 - 26281684

AN - SCOPUS:84941738355

SN - 0047-1852

VL - 73

SP - 1315

EP - 1322

JO - Nihon rinsho. Japanese journal of clinical medicine

JF - Nihon rinsho. Japanese journal of clinical medicine

IS - 8

ER -

PI3K and mTOR pathway and molecular targeted agents

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this